Eastwood Bio-Medical Canada Inc (TSE:EBM)

:EBM

EBM

Eastwood Bio-Medical Canada

RESEARCH TOOLSreports

Want to see TSE:EBM full AI Analyst Report?

Eastwood Bio-Medical Canada (EBM) Price & Analysis

5 Followers

EBM Stock Chart & Stats

C$0.80

>-C$0.01(-1.00%)

At close: Jan 08 4:00 PM EST

C$0.80

>-C$0.01(-1.00%)

Day’s Range― - ―

52-Week RangeC$0.30 - C$1.10

Previous CloseN/A

Volume2.20K

Average Volume (3M)3.49K

Market Cap

C$44.78M

Enterprise ValueC$65.33M

Total Cash (Recent Filing)C$13.46K

Total Debt (Recent Filing)C$74.67K

Price to Earnings (P/E)―

Beta-0.06

Next Earnings

Jul 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding68,885,970

10 Day Avg. Volume3,055

30 Day Avg. Volume3,488

Financial Highlights & Ratios

PEG Ratio5.31

Price to Book (P/B)-29.59

Price to Sales (P/S)61.66

P/FCF Ratio2.50K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA gross margin near 63% indicates durable unit economics from premium, formulation-driven products. That margin provides structural capacity to cover fixed costs, fund R&D and marketing, and absorb pricing pressure, supporting long-term profitability if SG&A is managed.

Improving Cash GenerationA shift back to positive operating and free cash flow, even small, signals operational improvement and reduces immediate liquidity strain. Sustained positive cash generation provides a foundation for self-funding working capital and reduces reliance on dilutive financing over the medium term.

Multi-channel Distribution & Research-backed ProductA diversified go-to-market mix and research-backed positioning create durable competitive advantages: multiple revenue paths reduce single-channel risk, while scientific credibility supports premium pricing and easier market entry or licensing in new geographies over time.

Bears Say

Negative Shareholders' EquityMaterial negative equity is a structural solvency concern that limits financial flexibility. It constrains borrowing capacity, raises creditor and counterparty risk, and increases likelihood of dilutive capital raises or restructuring if operating losses persist, impairing long-term stability.

Declining Revenue & Persistent LossesFalling revenue coupled with large negative margins signals difficulty converting product demand into sustainable profit. Without reversing top-line declines or meaningfully cutting fixed costs, the company risks continued erosion of reserves and hindered ability to invest for growth.

Small, Volatile Free Cash FlowAlthough cash flow turned positive, its small absolute size and recent decline (-25.9% vs prior) indicate volatility and limited cushion. This constrains reinvestment capacity and makes the business vulnerable to shocks or seasonality, likely necessitating external capital for expansion.

EBM FAQ

What was Eastwood Bio-Medical Canada Inc’s price range in the past 12 months?

Eastwood Bio-Medical Canada Inc lowest stock price was C$0.29 and its highest was C$1.10 in the past 12 months.

What is Eastwood Bio-Medical Canada Inc’s market cap?

Eastwood Bio-Medical Canada Inc’s market cap is C$44.78M.

When is Eastwood Bio-Medical Canada Inc’s upcoming earnings report date?

Eastwood Bio-Medical Canada Inc’s upcoming earnings report date is Jul 06, 2026 which is in 70 days.

How were Eastwood Bio-Medical Canada Inc’s earnings last quarter?

Currently, no data Available

Is Eastwood Bio-Medical Canada Inc overvalued?

According to Wall Street analysts Eastwood Bio-Medical Canada Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eastwood Bio-Medical Canada Inc pay dividends?

Eastwood Bio-Medical Canada Inc does not currently pay dividends.

What is Eastwood Bio-Medical Canada Inc’s EPS estimate?

Eastwood Bio-Medical Canada Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eastwood Bio-Medical Canada Inc have?

Eastwood Bio-Medical Canada Inc has 68,885,970 shares outstanding.

What happened to Eastwood Bio-Medical Canada Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Eastwood Bio-Medical Canada Inc?

Currently, no hedge funds are holding shares in TSE:EBM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.